BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Melnikov M, Sviridova A, Rogovskii V, Oleskin A, Boziki M, Bakirtzis C, Kesidou E, Grigoriadis N, Boykо A. Serotoninergic system targeting in multiple sclerosis: the prospective for pathogenetic therapy. Mult Scler Relat Disord 2021;51:102888. [PMID: 33756440 DOI: 10.1016/j.msard.2021.102888] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Stamoula Ε, Ainatzoglou A, Stamatellos V, Dardalas I, Siafis S, Matsas A, Stamoulas K, Papazisis G. Atypical antipsychotics in multiple sclerosis: A review of their in vivo immunomodulatory effects. Multiple Sclerosis and Related Disorders 2022;58:103522. [DOI: 10.1016/j.msard.2022.103522] [Reference Citation Analysis]
2 Sviridova A, Rogovskii V, Kudrin V, Pashenkov M, Boyko A, Melnikov M. The role of 5-HT2B-receptors in fluoxetine-mediated modulation of Th17- and Th1-cells in multiple sclerosis. J Neuroimmunol 2021;356:577608. [PMID: 34000471 DOI: 10.1016/j.jneuroim.2021.577608] [Reference Citation Analysis]
3 Melnikov M, Pashenkov M, Boyko A. Dopaminergic Receptor Targeting in Multiple Sclerosis: Is There Therapeutic Potential? Int J Mol Sci 2021;22:5313. [PMID: 34070011 DOI: 10.3390/ijms22105313] [Reference Citation Analysis]
4 Stamoula E, Siafis S, Dardalas I, Ainatzoglou A, Matsas A, Athanasiadis T, Sardeli C, Stamoulas K, Papazisis G. Antidepressants on Multiple Sclerosis: A Review of In Vitro and In Vivo Models. Front Immunol 2021;12:677879. [PMID: 34093579 DOI: 10.3389/fimmu.2021.677879] [Reference Citation Analysis]
5 Melnikov MV, Sviridova AA, Solodova TV, Lopatina AV, Pashenkov MV, Boyko AN. [Blockade of D1-like dopaminergic receptors suppresses Th17-cell function in multiple sclerosis]. Zh Nevrol Psikhiatr Im S S Korsakova 2021;121:82-9. [PMID: 34387452 DOI: 10.17116/jnevro202112107282] [Reference Citation Analysis]